-
Something wrong with this record ?
LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines
M. Krzyzankova, S. Chovanova, P. Chlapek, M. Radsetoulal, J. Neradil, K. Zitterbart, J. Sterba, R. Veselska,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1997-12-01 to 2015-12-31
Medline Complete (EBSCOhost)
from 2005-01-01 to 2016-12-31
Health & Medicine (ProQuest)
from 1997-12-01 to 2015-12-31
Public Health Database (ProQuest)
from 1997-12-01 to 2015-12-31
ROAD: Directory of Open Access Scholarly Resources
from 1987
- MeSH
- Cell Differentiation drug effects MeSH
- Cyclooxygenase Inhibitors pharmacology MeSH
- Lipoxygenase Inhibitors pharmacology MeSH
- Caffeic Acids pharmacology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Bone Neoplasms drug therapy pathology MeSH
- Osteosarcoma drug therapy pathology MeSH
- Cell Proliferation drug effects MeSH
- Antineoplastic Agents pharmacology MeSH
- Pyrazoles pharmacology MeSH
- Sulfonamides pharmacology MeSH
- Tretinoin pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The induced differentiation of tumor cells into mature phenotypes is a promising strategy in cancer therapy. In this study, the effects of combined treatment with all-trans retinoic acid (ATRA) and lipoxygenase/cyclooxygenase inhibitors were examined in two osteosarcoma cell lines, Saos-2 and OSA-01. Caffeic acid and celecoxib were used as inhibitors of 5-lipoxygenase and of cyclooxygenase-2, respectively. Changes in the cell proliferation, matrix mineralization, and occurrence of differentiation markers were evaluated in treated cell populations at intervals. The results confirmed the capability of caffeic acid to enhance the antiproliferative effect of ATRA in both cell lines. In contrast, celecoxib showed the same effect in Saos-2 cells only. Furthermore, the extension of matrix mineralization was observed after combined treatment with ATRA and celecoxib or caffeic acid. The increased expression of osteogenic differentiation markers was observed in both cell lines after the combined application of ATRA and inhibitors. The obtained results clearly demonstrate the capability of lipoxygenase/cyclooxygenase inhibitors to enhance the antiproliferative and differentiating effect of ATRA in osteosarcoma cells, although some of these effects are specific and depend on the biological features of the respective tumor or cell line.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014333
- 003
- CZ-PrNML
- 005
- 20150429115317.0
- 007
- ta
- 008
- 150420s2014 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13277-014-2019-5 $2 doi
- 035 __
- $a (PubMed)24798977
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Krzyzankova, Miroslava $u Laboratory of Tumor Biology, Department of Experimental Biology, School of Science, Masaryk University, Kotlarska 2, 611 37, Brno, Czech Republic.
- 245 10
- $a LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines / $c M. Krzyzankova, S. Chovanova, P. Chlapek, M. Radsetoulal, J. Neradil, K. Zitterbart, J. Sterba, R. Veselska,
- 520 9_
- $a The induced differentiation of tumor cells into mature phenotypes is a promising strategy in cancer therapy. In this study, the effects of combined treatment with all-trans retinoic acid (ATRA) and lipoxygenase/cyclooxygenase inhibitors were examined in two osteosarcoma cell lines, Saos-2 and OSA-01. Caffeic acid and celecoxib were used as inhibitors of 5-lipoxygenase and of cyclooxygenase-2, respectively. Changes in the cell proliferation, matrix mineralization, and occurrence of differentiation markers were evaluated in treated cell populations at intervals. The results confirmed the capability of caffeic acid to enhance the antiproliferative effect of ATRA in both cell lines. In contrast, celecoxib showed the same effect in Saos-2 cells only. Furthermore, the extension of matrix mineralization was observed after combined treatment with ATRA and celecoxib or caffeic acid. The increased expression of osteogenic differentiation markers was observed in both cell lines after the combined application of ATRA and inhibitors. The obtained results clearly demonstrate the capability of lipoxygenase/cyclooxygenase inhibitors to enhance the antiproliferative and differentiating effect of ATRA in osteosarcoma cells, although some of these effects are specific and depend on the biological features of the respective tumor or cell line.
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a nádory kostí $x farmakoterapie $x patologie $7 D001859
- 650 _2
- $a kyseliny kávové $x farmakologie $7 D002109
- 650 _2
- $a buněčná diferenciace $x účinky léků $7 D002454
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a inhibitory cyklooxygenasy $x farmakologie $7 D016861
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory lipoxygenas $x farmakologie $7 D016859
- 650 _2
- $a osteosarkom $x farmakoterapie $x patologie $7 D012516
- 650 _2
- $a pyrazoly $x farmakologie $7 D011720
- 650 _2
- $a sulfonamidy $x farmakologie $7 D013449
- 650 _2
- $a tretinoin $x farmakologie $7 D014212
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chovanova, Silvia
- 700 1_
- $a Chlapek, Petr
- 700 1_
- $a Radsetoulal, Matej
- 700 1_
- $a Neradil, Jakub
- 700 1_
- $a Zitterbart, Karel
- 700 1_
- $a Sterba, Jaroslav
- 700 1_
- $a Veselska, Renata
- 773 0_
- $w MED00008757 $t Tumour biology the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 35, č. 8 (2014), s. 7617-27
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24798977 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150429115621 $b ABA008
- 999 __
- $a ok $b bmc $g 1071914 $s 897211
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 35 $c 8 $d 7617-27 $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
- LZP __
- $a Pubmed-20150420